Pharmacological Ascorbate for Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2021

Study Completion Date

August 27, 2022

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Paclitaxel

"* Administered intravenously (IV)~* Prescribed at 200 mg/m2 (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response"

DRUG

Carboplatin

"* Administered intravenously (IV)~* Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response"

DRUG

Ascorbic Acid

"* Administered intravenously (IV)~* 75g per infusion~* Two infusions per week~* 1 cycle is 3 weeks~* given up to 4 cycles~* may be given while chemotherapy if delayed due to low counts"

Trial Locations (1)

52242

Holden Comprehensive Cancer Center, Iowa City

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Holden Comprehensive Cancer Center

OTHER

collaborator

McGuff Pharmaceuticals, Inc.

INDUSTRY

lead

Joseph J. Cullen, MD, FACS

OTHER

NCT02420314 - Pharmacological Ascorbate for Lung Cancer | Biotech Hunter | Biotech Hunter